Cbio A/S

Cbio A/S is a clinical stage cell therapy company started in 2019 focusing on Tumor Infiltrating Lymphocyte (TIL) therapy the most promising cell therapy for solid tumors. We have have developed a proprietary next-generation TIL manufacturing process with transformative potential. Our lead TIL therapy product, novoleucel, is now ready for clinical validation. We are located in Sborg (Copenhagen area), Denmark in a 1,000 m2 state-of-the-art facility where we develop and produce cell-based therapy products for clinical use

Cbio a/s operates in the Biotechnology research industry.

Cbio a/s's revenue is 11m - 100m

Cbio a/s has 11 - 50 employees.